NICE Downs GSK’s Benlysta In Second Lupus Indication On Comparator Grounds
This article was originally published in The Pink Sheet Daily
Executive Summary
In yet another knock-back of GSK’s lupus drug Benlysta in the U.K., NICE said cost and comparator issues were not adequately addressed by the British manufacturer.